1. Home
  2. QCLS vs ITRM Comparison

QCLS vs ITRM Comparison

Compare QCLS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCLS

Q/C Technologies Inc.

N/A

Current Price

$4.08

Market Cap

27.6M

Sector

Health Care

ML Signal

N/A

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

N/A

Current Price

$0.18

Market Cap

24.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCLS
ITRM
Founded
2014
2015
Country
United States
Ireland
Employees
2
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.6M
24.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
QCLS
ITRM
Price
$4.08
$0.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
836.6K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.14
52 Week High
$8.17
$1.49

Technical Indicators

Market Signals
Indicator
QCLS
ITRM
Relative Strength Index (RSI) 51.70 37.15
Support Level $4.00 N/A
Resistance Level $4.57 $0.39
Average True Range (ATR) 0.38 0.03
MACD 0.07 -0.00
Stochastic Oscillator 42.77 24.35

Price Performance

Historical Comparison
QCLS
ITRM

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: